Targeting PD-1/PD-L1 interactions for cancer immunotherapy

被引：296
|
作者：
Zitvogel, Laurence [1 ,2 ,3 ,4 ]
Kroemer, Guido [3 ,5 ,6 ,7 ,8 ]
机构：
[1] Inst Gustave Roussy, INSERM, U1015, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Ctr Clin Invest CBT507, Villejuif, France
[3] Inst Gustave Roussy, Villejuif, France
[4] Univ Paris 11, Villejuif, France
[5] INSERM, U848, Villejuif, France
[6] Ctr Rech Cordeliers, Paris, France
[7] Hop Europeen Georges Pompidou, Paris, France
[8] Univ Paris 05, Fac Med, Paris, France
来源：
ONCOIMMUNOLOGY | 2012年 / 1卷 / 08期
关键词：
CELL CARCINOMA PATIENTS; CLINICAL-SIGNIFICANCE; PD-1; PATHWAY; B7-H1; EXPRESSION; MOLECULE; IMMUNOSUPPRESSION; RECEPTORS; LIGAND-1; ANTIBODY;
D O I：
10.4161/onci.21335
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1223 / 1225
页数：3
相关论文
共 50 条
  • [21] Inhibitory Effect of PD-1/PD-L1 and Blockade Immunotherapy in Leukemia
    Xing, Kai
    Zhou, Pan
    Li, Jiaojiao
    Liu, Miao
    Zhang, Wei Emma
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2022, 25 (09) : 1399 - 1410
  • [22] PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
    Cantero-Cid, Ramon
    Casas-Martin, Jose
    Hernandez-Jimenez, Enrique
    Cubillos-Zapata, Carolina
    Varela-Serrano, Anibal
    Avendano-Ortiz, Jose
    Casarrubios, Marta
    Montalban-Hernandez, Karla
    Villacanas-Gil, Ignacio
    Guerra-Pastrian, Laura
    Peinado, Begona
    Marcano, Cristobal
    Aguirre, Luis A.
    Lopez-Collazo, Eduardo
    BMC CANCER, 2018, 18
  • [23] PD-1/PD-L1 in disease
    Kuol, Nyanbol
    Stojanovska, Lily
    Nurgali, Kulmira
    Apostolopoulos, Vasso
    IMMUNOTHERAPY, 2018, 10 (02) : 149 - 161
  • [24] Interplay between inflammasomes and PD-1/PD-L1 and their implications in cancer immunotherapy
    Jiao, Zhongyu
    Zhang, Jun
    CARCINOGENESIS, 2023, 44 (12) : 795 - 808
  • [25] PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
    Jiang, Yongshuai
    Chen, Ming
    Nie, Hong
    Yuan, Yuanyang
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (05) : 1111 - 1122
  • [26] Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1)
    Wen, Biyan
    Zhao, Lin
    Wang, Yuchu
    Qiu, Chuangnan
    Xu, Zhimin
    Huang, Kunling
    Zhu, He
    Li, Zemin
    Li, Huangjin
    PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY, 2020, 50 (03) : 252 - 259
  • [27] Treatment of of HIV/AIDS associated cancers with immunotherapy targeting PD-1/PD-L1 instead of chemotherapy
    Kasi, Pashtoon Murtaza
    Block, Matthew S.
    Ansell, Stephen M.
    MEDICAL HYPOTHESES, 2016, 86 : 129 - 131
  • [28] PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy
    Salmaninejad, Arash
    Valilou, Saeed Farajzadeh
    Shabgah, Arezoo Gowhari
    Aslani, Saeed
    Alimardani, Malihe
    Pasdar, Alireza
    Sahebkar, Amirhossein
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (10) : 16824 - 16837
  • [29] Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy
    Hu, Xiaoli
    Wang, Jing
    Chu, Man
    Liu, Yi
    Wang, Zhi-wei
    Zhu, Xueqiong
    MOLECULAR THERAPY, 2021, 29 (03) : 908 - 919
  • [30] Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy
    Jiao, Peifu
    Geng, Qiaohong
    Jin, Peng
    Su, Gaoxing
    Teng, Houyun
    Dong, Jinlong
    Yan, Bing
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (41) : 4911 - 4920
12345